Canagliflozin vs Humanin
A side-by-side research comparison of Canagliflozin and Humanin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | Humanin |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | Humanin (HN) Mitochondrial-Derived Peptide |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Research compound |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. |
| Molecular weight | 444.52 Da | 2,687 Da |
| Half-life | ~11-13 hours | 4-6 hours |
| Bioavailability | ~65% oral | Moderate (SubQ) |
| Typical dose | 100-300 mg per day | 1-5 mg |
| Frequency | Once daily | 3-5x per week |
| Route | Oral tablet | Subcutaneous |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Related comparisons
Research and educational reference only. Not medical advice.